The Foundation for the National Institute of Health Seeks Public Comment - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

The Foundation for the National Institute of Health Seeks Public Comment


ePT--the Electronic Newsletter of Pharmaceutical Technology

The Observational Medical Outcomes Partnership (OMOP), a public–private partnership managed by the nonprofit Foundation for the National Institutes of Health and chaired by FDA, conducts methodological research on the use of observational healthcare data in studying the effects of medical products. The OMOP executive board is seeking public feedback on the priorities, infrastructure tasks, and research tasks it has proposed for 2013–2016.  Comments are being collected via the OMOP website through Sept. 15, 2012.

“Receiving public feedback regarding OMOP’s work is vital to our success,” said OMOP executive board member, Ronald Krall, MD, in an Aug. 27, 2012 press release. “We want to make sure we hear every idea about how to use healthcare data to improve the safety and effectiveness of medical products.”

OMOP was formed in 2008, and the group’s research since then has affirmed its belief that the science of observational research requires an empirical and reproducible approach to methodology and systematic application.  OMOP’s research has generated empirical evidence about the ability of observational analysis methods to identify true risks of medical products and discriminate from false findings.  Experiments were designed to understand how an estimated effect from an observational study relates to the true relationship between medical product exposure and adverse events.

Proposed priorities for upcoming research, described in the OMOP Call for Comments, include creating a foundation for the common representation of healthcare data, developing empirical evidence to support study of the association between medical interventions and adverse outcomes, developing empirical evidence to aid detection of unsuspected associations between medical events and interventions, and creating a framework for evidence-based decision making.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here